<DOC>
	<DOCNO>NCT02502149</DOCNO>
	<brief_summary>The primary objective study compare pharmacokinetic ( PK ) recombinant coagulation factor VIII Fc fusion protein ( rFVIIIFc ) manufacture current scale 2000 L ( 2K ) PK rFVIIIFc manufacture 15,000 L ( 15K ) scale previously treat participant severe hemophilia A . The secondary objective : characterize PK rFVIIIFc manufacture 15K scale 15K baseline 13 week treatment ; characterize PK rFVIIIFc manufacture 15K scale 1000 IU/vial high strength vial ; evaluate safety rFVIIIFc manufacture 15K scale .</brief_summary>
	<brief_title>Pharmacokinetics Safety rFVIIIFc Manufactured 15,000 L ( 15K ) Scale</brief_title>
	<detailed_description>PK assessments 3 phase : PK1 : PK assessment follow single injection rFVIIIFc manufacture 2K scale . PK2 : PK assessment make follow single injection rFVIIIFc manufacture 15K scale participant randomized 1000 IU vial high strength vial . PK3 : PK assessment make follow 13 week rFVIIIFc treatment manufacture 15K scale participant randomized 1000 IU vial high strength vial . After study completion , country rFVIIIFc commercially available , eligible participant offer enrollment long-term safety efficacy extension study ( 8HA01EXT [ NCT01454739 ] ) .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Key Have severe hemophilia A , define &lt; 1 IU/dL ( &lt; 1 % ) endogenous FVIII determine onestage clot assay central laboratory Screening . Previously treat subject , define least 150 documented prior exposure day ( EDs ) recombinant and/or plasmaderived FVIII and/or cryoprecipitate product Day 1 . Fresh frozen plasma treatment must consider count document exposure day . No history positive inhibitor test clinical sign decrease response FVIII administration . Family history inhibitor exclude subject . No measurable inhibitor activity use Nijmegenmodified Bethesda assay ( â‰¥0.6 BU/mL consider positive ) Screening . Key Current enrollment interventional clinical study investigational drug approve therapy investigational use administer within 30 day prior Baseline Visit OR prior participation follow Biogen study : 998HA101 ( NCT01027377 ) , 997HA301 ( NCT01181128 ) , 8HA02PED ( NCT01458106 ) , 997HA307 ( NCT02083965 ) , 8HA01EXT ( NCT01454739 ) . Previous participation study . Any concurrent clinically significant major disease , opinion Investigator Biogen , make subject unsuitable participation study . Other coagulation disorder ( ) addition hemophilia A . History hypersensitivity anaphylaxis associate FVIII intravenous ( IV ) immunoglobulin administration . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>rFVIIIFc</keyword>
	<keyword>Eloctate</keyword>
	<keyword>Hemophilia</keyword>
</DOC>